Last reviewed · How we verify
NCT06326840
Clinical Efficacy and Adverse Reactions of Antipsychotic Treatment
NA trial testing Metformin in Metabolic Disturbance in 42 participants. Completed in 10 June 2011.
10 June 2011
Quick facts
| Lead sponsor | Taipei Medical University Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 42 |
| Start date | 31 May 2010 |
| Primary completion | 10 June 2011 |
| Estimated completion | 10 June 2011 |
| Sites | 1 location across Taiwan |
Drugs / interventions tested
- Metformin (metformin) — full drug profile →
Conditions studied
- Metabolic Disturbance — all drugs for Metabolic Disturbance →
- Hyperprolactinemia — all drugs for Hyperprolactinemia →
- Schizophrenia — all drugs for Schizophrenia →
Sponsor
Taipei Medical University Hospital
Who can join
Adults 18 to 60, any sex, with Metabolic Disturbance or Hyperprolactinemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to explore the potential of metformin in managing olanzapine-induced metabolic disturbance and hyperprolactinemia in patients with schizophrenia. The main questions it aims to answer are: 1. The effect of metformin on olanzapine-induced metabolic disturbance 2. The effect of metformin on olanzapine-induced hyperprolactinemia Participants will receive metformin 1500 mg/day for 8 weeks and assessments every 2 weeks.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06326840
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Metformin
Trials testing the same drug.
- NCT07275359 — Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations · Phase 1 · not yet recruiting
- NCT07520110 — Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis · Phase 3 · not yet recruiting
- NCT07007221 — Clinical Trials to Evaluate Metformin to Treat Depression in People Living With HIV · Phase 2 · not yet recruiting
- NCT07585396 — Inositol in Letrozol Resistant PCOS Women · Phase 2, PHASE3 · not yet recruiting
- NCT07226453 — Target Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) Ependymoma · Phase 2 · not yet recruiting
Other recruiting trials for Metabolic Disturbance
Currently open trials in the same condition.
- NCT06454864 — Multiple Risk Factor Intervention Trial in Breast Cancer Survivors · NA · recruiting
- NCT06345937 — Multiple Risk Factor Intervention Trial (Ms. FIT) · NA · recruiting
- NCT06252922 — Diet-Induced Changes in GEnetic Material · recruiting
- NCT05919940 — Improved Muscle Metabolism by Combination of Muscle Activation and Protein Substitution ( IMEMPRO ) · NA · recruiting
- NCT05912348 — The Effects of an Obesogenic Lifestyle in Recreationally Active, Young Adults · NA · recruiting
Other Taipei Medical University Hospital trials
Trials by the same sponsor.
- NCT07294469 — Menthol for Improving Movement and Sleep in Parkinson's Disease Patients · Phase 2 · not yet recruiting
- NCT07114289 — Spontaneous Breathing Trials Using Pressure Support or T-Piece in Overweight and Obese Patients · NA · recruiting
- NCT06949618 — Repetitive Transcranial Magnetic Stimulation in Cancer Pain Management · NA · not yet recruiting
- NCT05830578 — Clinical Validation of the Electrocardiogram Measurement · unknown
- NCT05877079 — TRPM8 in Acute Ischemic Stroke by Topical Menthol · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06326840 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Taipei Medical University Hospital
- Last refreshed: 22 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06326840.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing